Compare Merck & Co., Inc. (MRK) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nano Dimension Ltd - ADR — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M). The key difference: Merck & Co., Inc. is far larger — about 1069.3× Nano Dimension Ltd - ADR's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| MRK | NNDM | |
|---|---|---|
Market Cap | $351.28B | $328.52M |
Volume | 7,969,665 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $156.43 | $2.14 |
52-Week Low | $82.49 | $1.21 |
Typical Hold Time | 98 Days | 43 Days |
Enterprise Value | $398.04B | -$76.33M |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Nano Dimension (NNDM) trades at $1.56, up 0.65% with a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but remains unprofitable with a -135% net margin. Recent strategic actions include cost-cutting initiatives and board changes, with cash reserves of $758M providing operational runway despite negative cash flows.
The outlook remains challenging with persistent losses and negative cash flow, though valuation ratios appear attractive with P/S of 2.73 and P/B of 0.68. Key risks include execution of turnaround strategy and competitive pressures in the industrial 3D printing sector. Analyst sentiment is cautious given the company's ongoing restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
